Cargando…

Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya

BACKGROUND: Controlled human malaria infection (CHMI) studies, in which healthy volunteers are infected with Plasmodium falciparum to assess the efficacy of novel malaria vaccines and drugs, have become a vital tool to accelerate vaccine and drug development. CHMI studies provide a cost-effective an...

Descripción completa

Detalles Bibliográficos
Autores principales: Hodgson, Susanne H, Juma, Elizabeth, Salim, Amina, Magiri, Charles, Njenga, Daniel, Molyneux, Sassy, Njuguna, Patricia, Awuondo, Ken, Lowe, Brett, Billingsley, Peter F, Cole, Andrew O, Ogwang, Caroline, Osier, Faith, Chilengi, Roma, Hoffman, Stephen L, Draper, Simon J, Ogutu, Bernhards, Marsh, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416324/
https://www.ncbi.nlm.nih.gov/pubmed/25927522
http://dx.doi.org/10.1186/s12936-015-0671-x
_version_ 1782369217944748032
author Hodgson, Susanne H
Juma, Elizabeth
Salim, Amina
Magiri, Charles
Njenga, Daniel
Molyneux, Sassy
Njuguna, Patricia
Awuondo, Ken
Lowe, Brett
Billingsley, Peter F
Cole, Andrew O
Ogwang, Caroline
Osier, Faith
Chilengi, Roma
Hoffman, Stephen L
Draper, Simon J
Ogutu, Bernhards
Marsh, Kevin
author_facet Hodgson, Susanne H
Juma, Elizabeth
Salim, Amina
Magiri, Charles
Njenga, Daniel
Molyneux, Sassy
Njuguna, Patricia
Awuondo, Ken
Lowe, Brett
Billingsley, Peter F
Cole, Andrew O
Ogwang, Caroline
Osier, Faith
Chilengi, Roma
Hoffman, Stephen L
Draper, Simon J
Ogutu, Bernhards
Marsh, Kevin
author_sort Hodgson, Susanne H
collection PubMed
description BACKGROUND: Controlled human malaria infection (CHMI) studies, in which healthy volunteers are infected with Plasmodium falciparum to assess the efficacy of novel malaria vaccines and drugs, have become a vital tool to accelerate vaccine and drug development. CHMI studies provide a cost-effective and expeditious way to circumvent the use of large-scale field efficacy studies to deselect intervention candidates. However, to date few modern CHMI studies have been performed in malaria-endemic countries. METHODS: An open-label, randomized pilot CHMI study was conducted using aseptic, purified, cryopreserved, infectious P. falciparum sporozoites (SPZ) (Sanaria® PfSPZ Challenge) administered intramuscularly (IM) to healthy Kenyan adults (n = 28) with varying degrees of prior exposure to P. falciparum. The purpose of the study was to establish the PfSPZ Challenge CHMI model in a Kenyan setting with the aim of increasing the international capacity for efficacy testing of malaria vaccines and drugs, and allowing earlier assessment of efficacy in a population for which interventions are being developed. This was part of the EDCTP-funded capacity development of the CHMI platform in Africa. DISCUSSION: This paper discusses in detail lessons learnt from conducting the first CHMI study in Kenya. Issues pertinent to the African setting, including community sensitization, consent and recruitment are considered. Detailed reasoning regarding the study design (for example, dose and route of administration of PfSPZ Challenge, criteria for grouping volunteers according to prior exposure to malaria and duration of follow-up post CHMI) are given and changes other centres may want to consider for future studies are suggested. CONCLUSIONS: Performing CHMI studies in an African setting presents unique but surmountable challenges and offers great opportunity for acceleration of malaria vaccine and drug development. The reflections in this paper aim to aid other centres and partners intending to use the CHMI model in Africa. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-015-0671-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4416324
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44163242015-05-02 Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya Hodgson, Susanne H Juma, Elizabeth Salim, Amina Magiri, Charles Njenga, Daniel Molyneux, Sassy Njuguna, Patricia Awuondo, Ken Lowe, Brett Billingsley, Peter F Cole, Andrew O Ogwang, Caroline Osier, Faith Chilengi, Roma Hoffman, Stephen L Draper, Simon J Ogutu, Bernhards Marsh, Kevin Malar J Case Study BACKGROUND: Controlled human malaria infection (CHMI) studies, in which healthy volunteers are infected with Plasmodium falciparum to assess the efficacy of novel malaria vaccines and drugs, have become a vital tool to accelerate vaccine and drug development. CHMI studies provide a cost-effective and expeditious way to circumvent the use of large-scale field efficacy studies to deselect intervention candidates. However, to date few modern CHMI studies have been performed in malaria-endemic countries. METHODS: An open-label, randomized pilot CHMI study was conducted using aseptic, purified, cryopreserved, infectious P. falciparum sporozoites (SPZ) (Sanaria® PfSPZ Challenge) administered intramuscularly (IM) to healthy Kenyan adults (n = 28) with varying degrees of prior exposure to P. falciparum. The purpose of the study was to establish the PfSPZ Challenge CHMI model in a Kenyan setting with the aim of increasing the international capacity for efficacy testing of malaria vaccines and drugs, and allowing earlier assessment of efficacy in a population for which interventions are being developed. This was part of the EDCTP-funded capacity development of the CHMI platform in Africa. DISCUSSION: This paper discusses in detail lessons learnt from conducting the first CHMI study in Kenya. Issues pertinent to the African setting, including community sensitization, consent and recruitment are considered. Detailed reasoning regarding the study design (for example, dose and route of administration of PfSPZ Challenge, criteria for grouping volunteers according to prior exposure to malaria and duration of follow-up post CHMI) are given and changes other centres may want to consider for future studies are suggested. CONCLUSIONS: Performing CHMI studies in an African setting presents unique but surmountable challenges and offers great opportunity for acceleration of malaria vaccine and drug development. The reflections in this paper aim to aid other centres and partners intending to use the CHMI model in Africa. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-015-0671-x) contains supplementary material, which is available to authorized users. BioMed Central 2015-04-28 /pmc/articles/PMC4416324/ /pubmed/25927522 http://dx.doi.org/10.1186/s12936-015-0671-x Text en © Hodgson et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Study
Hodgson, Susanne H
Juma, Elizabeth
Salim, Amina
Magiri, Charles
Njenga, Daniel
Molyneux, Sassy
Njuguna, Patricia
Awuondo, Ken
Lowe, Brett
Billingsley, Peter F
Cole, Andrew O
Ogwang, Caroline
Osier, Faith
Chilengi, Roma
Hoffman, Stephen L
Draper, Simon J
Ogutu, Bernhards
Marsh, Kevin
Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya
title Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya
title_full Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya
title_fullStr Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya
title_full_unstemmed Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya
title_short Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya
title_sort lessons learnt from the first controlled human malaria infection study conducted in nairobi, kenya
topic Case Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416324/
https://www.ncbi.nlm.nih.gov/pubmed/25927522
http://dx.doi.org/10.1186/s12936-015-0671-x
work_keys_str_mv AT hodgsonsusanneh lessonslearntfromthefirstcontrolledhumanmalariainfectionstudyconductedinnairobikenya
AT jumaelizabeth lessonslearntfromthefirstcontrolledhumanmalariainfectionstudyconductedinnairobikenya
AT salimamina lessonslearntfromthefirstcontrolledhumanmalariainfectionstudyconductedinnairobikenya
AT magiricharles lessonslearntfromthefirstcontrolledhumanmalariainfectionstudyconductedinnairobikenya
AT njengadaniel lessonslearntfromthefirstcontrolledhumanmalariainfectionstudyconductedinnairobikenya
AT molyneuxsassy lessonslearntfromthefirstcontrolledhumanmalariainfectionstudyconductedinnairobikenya
AT njugunapatricia lessonslearntfromthefirstcontrolledhumanmalariainfectionstudyconductedinnairobikenya
AT awuondoken lessonslearntfromthefirstcontrolledhumanmalariainfectionstudyconductedinnairobikenya
AT lowebrett lessonslearntfromthefirstcontrolledhumanmalariainfectionstudyconductedinnairobikenya
AT billingsleypeterf lessonslearntfromthefirstcontrolledhumanmalariainfectionstudyconductedinnairobikenya
AT coleandrewo lessonslearntfromthefirstcontrolledhumanmalariainfectionstudyconductedinnairobikenya
AT ogwangcaroline lessonslearntfromthefirstcontrolledhumanmalariainfectionstudyconductedinnairobikenya
AT osierfaith lessonslearntfromthefirstcontrolledhumanmalariainfectionstudyconductedinnairobikenya
AT chilengiroma lessonslearntfromthefirstcontrolledhumanmalariainfectionstudyconductedinnairobikenya
AT hoffmanstephenl lessonslearntfromthefirstcontrolledhumanmalariainfectionstudyconductedinnairobikenya
AT drapersimonj lessonslearntfromthefirstcontrolledhumanmalariainfectionstudyconductedinnairobikenya
AT ogutubernhards lessonslearntfromthefirstcontrolledhumanmalariainfectionstudyconductedinnairobikenya
AT marshkevin lessonslearntfromthefirstcontrolledhumanmalariainfectionstudyconductedinnairobikenya